Comparative Study on the Safety and Efficacy of Aspirin plus Rivaroxaban vs Clopidogrel plus Apixaban in Deep Vein Thrombosis Patients

Q: What are the key findings of this study?

Clopidogrel plus Apixaban reduced DVT recurrence to 5% compared to 45% with Aspirin plus Rivaroxaban (p=0.0035) in patients with DVT over one year.

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Deep Vein Thrombosis (n=40). Intervention: Clopidogrel + Apixaban vs. Aspirin + Rivaroxaban. Primary outcome: Incidence of DVT recurrence and progression (p=0.0035 for recurrence, p=0.0035).

Neeraj Moitra

doi:10.64388/irev9i8-1714291

February 23, 2026Iconic Research and Engineering JournalsOpen Access

Comparative Study on the Safety and Efficacy of Aspirin plus Rivaroxaban vs Clopidogrel plus Apixaban in Deep Vein Thrombosis Patients

View Full Paper

Ask AI

Bookmark

Share

Key result

Clopidogrel plus apixaban linked to ~89% lower DVT recurrence versus aspirin plus rivaroxaban.

p=0.0035 for recurrence
P=0.0035
n=40

Why the study?

The study was designed to compare the effectiveness and safety profiles of aspirin plus rivaroxaban versus clopidogrel plus apixaban in minimizing thromboembolic risks in patients with deep vein thrombosis.

Does Apixaban plus Clopidogrel reduce DVT recurrence and progression compared to Rivaroxaban plus Aspirin in patients with Deep Vein Thrombosis?

Key Points

To compare the efficacy and safety of aspirin plus rivaroxaban versus clopidogrel plus apixaban in reducing thromboembolic risk in patients with deep vein thrombosis.
Conducted a prospective observational study at Malla Reddy Narayana Multispeciality Hospital (2023–2024) including 40 patients aged 18 and older with confirmed DVT.
Allocated participants evenly into two groups: Apixaban 5mg twice daily plus Clopidogrel 75mg once daily (CA group) or Rivaroxaban 20mg once daily plus Aspirin 100mg once daily (RA group).
Evaluated primary outcomes of DVT recurrence and progression, alongside secondary endpoints of major and minor bleeding, mortality, and laboratory parameters using Chi-square and T-tests in SPSS v26.0.
Patients receiving clopidogrel plus apixaban had a significantly lower rate of DVT recurrence compared to aspirin plus rivaroxaban (5% vs. 45%; p= 0.0035), with a trend toward decreased disease progression (10% vs. 35%; p = 0.051).
Safety outcomes showed no statistically significant differences in major bleeding (10% vs. 25%; p=0.20), minor bleeding (20% vs. 35%; p=0.27), or mortality (5% vs. 10%; p=1.00).
Baseline laboratory metrics differed significantly between groups, with higher baseline INR (1.62 vs. 1.21, p<0.001) and lower hemoglobin (12.3 vs. 13.7g/dL, p=0.001) in the RA cohort.

Study Design

Type

Observational (n=40)

Multicenter

No

Structured PICO

Does Apixaban plus Clopidogrel reduce DVT recurrence and progression compared to Rivaroxaban plus Aspirin in patients with Deep Vein Thrombosis?

P

Population

40 patients aged 18 and older with confirmed Deep Vein Thrombosis (DVT). Exclusions: bleeding disorders, pregnant women, and patients with severe hepatic/renal disorders.

I

Intervention

Apixaban 5 mg twice daily plus Clopidogrel 75 mg once daily

C

Comparator

Rivaroxaban 20 mg once daily plus Aspirin 100 mg once daily

O

Outcome

Incidence of DVT recurrence and progressionhard clinical

Main Result

Effect estimate: p=0.0035 for recurrence

Absolute Event Rate: 5% vs 45%

p-value: p=0.0035

In patients with DVT, a combination of Clopidogrel and Apixaban significantly reduced DVT recurrence compared to Aspirin and Rivaroxaban without a significant increase in bleeding, though baseline imbalances limit the strength of these findings.

Limitations

Small sample size of 40 participants
Observational study design without randomization
Limited follow-up duration of one year
Small sample size
Observational nature
Limited follow-up duration
Baseline laboratory value imbalances (confounding factors)

Implication

Clopidogrel plus apixaban was associated with lower DVT recurrence than aspirin plus rivaroxaban without excess bleeding; leaves open superiority pending randomized trials.

Abstract

Background: This research aims to evaluate and contrast the effectiveness and safety profiles of Aspirin with Rivaroxaban (RA) and Clopidogrel with Apixaban (CA) in minimizing thromboembolic risks among patients diagnosed with Deep Vein Thrombosis (DVT). Methodology: A forward-looking observational study was conducted involving 40 participants with confirmed DVT, allocated evenly between two treatment groups. Parameters assessed included recurrence and progression of DVT, bleeding events, death rates, and relevant laboratory markers. Data analysis involved Chi-square and T-tests using SPSS v26.0. Findings: The patients in the CA group had a significantly lower rate of DVT recurrence (5% vs. 45%; p= 0.0035) and a tendency towards less disease progression (10% vs. 35%; p = 0.051). The incidence of major and mild hemorrhage, as well as fatality rates, did not exhibit significant differences. However, the baseline INR, haemoglobin, and platelet count were significantly different (p<0.05) from the normal range. Conclusion: Clopidogrel-apixaban seemed to be more effective in the prevention of DVT recurrence without increasing the risk to the patients’ safety compared to Aspirin-Rivaroxaban. This study needs to be followed by broader, randomised trials to confirm these findings.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Neeraj Moitra (2026) conducted an observational in Deep Vein Thrombosis (n=40). Clopidogrel + Apixaban vs. Aspirin + Rivaroxaban was evaluated on Incidence of DVT recurrence and progression (p=0.0035 for recurrence, p=0.0035). Clopidogrel plus Apixaban reduced DVT recurrence to 5% compared to 45% with Aspirin plus Rivaroxaban (p=0.0035) in patients with DVT over one year.

synapsesocial.com/papers/699fe28895ddcd3a253e64f0 https://doi.org/10.64388/irev9i8-1714291

View Full Paper

Ask AI

Bookmark

Share

Comparative Study on the Safety and Efficacy of Aspirin plus Rivaroxaban vs Clopidogrel plus Apixaban in Deep Vein Thrombosis Patients

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Comparative Study on the Safety and Efficacy of Aspirin plus Rivaroxaban vs Clopidogrel plus Apixaban in Deep Vein Thrombosis Patients

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading